Clinical Trial Detail

NCT ID NCT02575404
Title GR-MD-02 Plus Pembrolizumab in Melanoma Patients
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Providence Health & Services
Indications

melanoma

Therapies

Belapectin

Pembrolizumab

Age Groups: adult

No variant requirements are available.